<DOC>
	<DOCNO>NCT03086330</DOCNO>
	<brief_summary>This trial conduct Asia , Europe North America . The aim trial compare effect semaglutide s.c. 1.0 mg once-weekly versus placebo add-on sodium glucose co-transporter-2 inhibitor ( SGLT-2i ) monotherapy combination either metformin sulfonylurea glycaemic control 30 week treatment subject type 2 diabetes . Subjects remain pre-trial medication .</brief_summary>
	<brief_title>Efficacy Safety Semaglutide Once-weekly Versus Placebo add-on SGLT-2i Subjects With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Informed consent obtain trialrelated activity . Trialrelated activity procedure carry part trial , include activity determine suitability trial Male female , equal 18 year time signing informed consent . For Japan : Male female , age equal 20 year time signing informed consent Diagnosed type 2 diabetes mellitus HbA1c 7.010.0 % ( 5386 mmol/mol ) ( inclusive ) Stable dose SGLT2 inhibitor monotherapy combination ( include fixeddose drug combination ) stable dose metformin ( equal 1500 mg maximum tolerate dose ) SU least 90 day prior day screen . All medication compliance current local label Female pregnant , breastfeed intend become pregnant childbearing potential use adequate contraceptive method ( adequate contraceptive measure require local regulation practice ) Any disorder investigator 's opinion might jeopardise subject 's safety compliance protocol Treatment medication indication diabetes obesity state inclusion criterion within past 90 day prior day screen . However , short term insulin treatment maximum 14 day prior day screen allow Subjects alanine aminotransferase 2.5 x upper normal limit Family personal history multiple endocrine neoplasia type 2 medullary thyroid carcinoma . Family define first degree relative History presence pancreatitis ( acute chronic ) History diabetic ketoacidosis Any following : myocardial infarction , stroke , hospitalization unstable angina transient ischaemic attack within past 180 day prior day screen Subjects presently classify New York Heart Association Class IV Planned coronary , carotid peripheral artery revascularisation know day screen Renal impairment measure estimate Glomerular Filtration Rate value eGFR 60 ml/min/1.73 m^2 define KDIGO 2012 classification use isotope dilution mass spectrometry serum creatinine measure screen Proliferative retinopathy maculopathy require acute treatment . Verified fundus photography dilate fundoscopy perform within past 90 day prior randomisation Presence history malignant neoplasm within past 5 year prior day screen . Basal squamous cell skin cancer carcinoma insitu allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>